Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pfizer’s group B streptococcus vaccine candidate wins Breakthrough Therapy Designation from FDA

By Brian Buntz | September 7, 2022

PfizerFDA has granted Pfizer’s (NYSE:PFE) investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, Breakthrough Therapy Designation.

The designation covers active immunization of mothers during pregnancy to confer protection against invasive GBS disease in newborns and young infants.

GBS disease can result in lifelong neurologic impairments or death, according to a 2019 article in the Journal of Infectious Diseases.

The six most common GBS serotypes cause approximately 98% of GBS disease globally.

Group B streptococcus has been the most common cause of sepsis in newborns since the 1970s, according to the CDC.

The incidence of group B streptococcus has also risen in nonpregnant adults in recent decades, according to a 2019 study published in JAMA. In adults, chronic conditions such as obesity and diabetes may be associated with an elevated risk of contracting GBS.

The FDA’s recent decision is based on data from an interim analysis of a placebo-controlled Phase 2 study (NCT03765073) testing GBS6 in healthy pregnant women between 18 and 40. The women in the study received the vaccine in the second or early third trimester.

The ongoing observer-blinded NCT03765073 study has approximately 586 subjects.

Treatment options to reduce the risk of GBS include prenatal screening and antibiotics during childbirth.

Those options, however, are not fully protective in the first week of life and can be challenging in low- and middle-income countries, according to Annaliesa Anderson, senior vice president and head of vaccine research and development at Pfizer. Additionally, current treatments have “not been shown effective in preventing disease globally in infants beyond the first week of life and through the vulnerable first three months of life,” said Anderson in a news release.

Pfizer anticipates that GBS6, if approved, could help reduce the risk of GBS-related conditions such as meningitis, pneumonia and sepsis.

GBS6 is a hexavalent capsular polysaccharide conjugate vaccine.

PFE shares ticked up 0.81% to $46.13 today.

FDA created the Breakthrough Therapy Designation to accelerate the development and review of therapies that can treat or prevent serious conditions. In awarding the designation, the agency looks for data suggesting that an investigational therapy could lead to substantial improvement in at least one clinically significant endpoint over currently available treatment options.


Filed Under: clinical trials, Infectious Disease
Tagged With: group B streptococcus
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE